retatrutide resting heart rate and Issues: Cardiovascular Effects, Risks, and Safety – Bolt Pharmacy Retatrutide Increase Heart Rate

Separately, starting July 1, 2026, the Medicare GLP-1 Bridge, a national CMS demonstration, gives eligible Part D beneficiaries Wegovy, Foundayo, or the Zepbound KwikPen at a flat $50 per month through 2027

Food and Drug Administration (FDA) approved Foundayo on April 1, 2026, marking Lillys entry into the oral weight-loss market

Am J Physiol Liver Physiol 293:G211G221

The card doesnt work if youre uninsured

MeAgain is the best default GLP-1 side effect tracker app if you want symptoms connected to the rest of your GLP-1 routine: dose day, shots or pills, food, protein, fiber, water, weight, progress, and other logs

Tirzepatide: available and gaining ground Tirzepatide is FDA-approved as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management)